Simple Summary Biochemical incomplete response (BIR) is defined as elevated
thyroglobulin or rising thyroglobulin antibodies following treatment without structural …

Objective Little is known regarding parameters predicting persistence/recurrence for
differentiated thyroid cancer (DTC) patients exhibiting biochemical incomplete response …

Purpose The aim of this study was to evaluate the long-term clinical outcomes of papillary
thyroid carcinoma (PTC) patients exhibiting biochemical incomplete response (BIR) to initial …

Purpose The aim of this study was evaluate biochemical incomplete response (BIR) in
Middle Eastern differentiated thyroid cancer (DTC), identify factors that could predict BIR …

Background: We previously demonstrated the clinical utility of using response to therapy
variables obtained during the first 2 years of follow-up to actively modify initial risk estimates …

The last 10 years has seen a renewed interest in a risk adapted management approach to
differentiated thyroid cancer. We now view risk stratification as an ongoing, dynamic process …

Background Dynamic risk stratification is utilized in the follow-up of patients with papillary
thyroid carcinoma (PTC). Analysis of outcomes after biochemical incomplete response (BIR) …

Background: Molecular testing (MT) is emerging as a potential prognostic factor that can be
available before treatment of differentiated thyroid carcinoma begins. Among patients …

The clinical outcome of papillary thyroid carcinoma (PTC) patients with an indeterminate
response after initial therapy is reported to be intermediate, between incomplete and …

Context Controversy surrounds the extent and intensity of the management of American
Thyroid Association (ATA) intermediate-and low-risk patients with differentiated thyroid …